Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma.

Abstract

Objective: Compare health-related quality of life (HRQoL) of selinexor versus placebo in patients with dedifferentiated liposarcoma. Materials & methods: HRQoL was assessed at baseline and day 1 of each cycle using the European Organization for Research and Treatment of Cancer 30-item core quality of life questionnaire. Results were reported from baseline to day 169 (where exposure to treatment was maximized while maintaining adequate sample size). Results: Pain scores worsened for placebo versus selinexor across all postbaseline visits, although differences in HRQoL at some visits were not significant. Other domains did not exhibit significant differences between arms; however, scores in both arms deteriorated over time. Conclusion: Patients treated with selinexor reported lower rates and slower worsening of pain compared with patients who received placebo.

• Authors: Mrinal Gounder, Albiruni R Abdul Razak, Adrienne M Gilligan, Hoyee Leong, Xiwen Ma, Neeta Somaiah, Sant P Chawla, Javier Martin-Broto, Giovanni Grignani, Scott M Schuetze, Bruno Vincenzi, Andrew J Wagner, Bartosz Chmielowski, Robin L Jones, Jatin Shah, Sharon Shacham, Michael Kauffman, Richard F Riedel, Steven Attia
• Journal: Future oncology (London, England) (Future Oncol) Vol. 17 Issue 22 Pg. 2923-2939 (Aug 2021) ISSN: 1744-8301 [Electronic] England
• PMID: 33855868 (Publication Type: Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial)

Chemical References

• Hydrazines
• Placebos
• Triazoles
• selinexor

Topics

• Adult
• Aged
• Aged, 80 and over
• Cancer Pain (diagnosis, drug therapy, etiology, psychology)
• Cross-Over Studies
• Female
• Humans
• Hydrazines (administration & dosage, adverse effects)
• Liposarcoma (complications, diagnosis, drug therapy, pathology)
• Male
• Middle Aged
• Neoplasm Staging
• Placebos (administration & dosage, adverse effects)
• Quality of Life
• Triazoles (administration & dosage, adverse effects)